NasdaqGM:ZNTLBiotechs
Is Zentalis (ZNTL) Using Azenosertib’s New Dose To Reframe Its Ovarian Cancer Strategy?
Zentalis Pharmaceuticals recently reported that a 400mg once-daily, 5-days-on/2-days-off regimen of azenosertib was selected as the optimal monotherapy dose for Cyclin E1-positive platinum-resistant ovarian cancer, following a prespecified interim analysis from the DENALI Part 2a Phase 2 trial.
This dose decision, supported by a differentiated response rate, comparable safety and plans for inclusion in both the pivotal DENALI Phase 2 and confirmatory ASPENOVA Phase 3 trials, is central to...